{"id":147764,"date":"2025-10-06T09:57:14","date_gmt":"2025-10-06T07:57:14","guid":{"rendered":"https:\/\/www.startupbusiness.it\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/"},"modified":"2025-10-06T12:45:25","modified_gmt":"2025-10-06T10:45:25","slug":"e83-5-million-series-a-round-for-biotech-company-nanophoria","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/","title":{"rendered":"\u20ac83.5 million Series A round for biotech company NanoPhoria"},"content":{"rendered":"\n<p><strong>NanoPhoria Bioscience, a biotech company based in Milan, has announced that it has closed its Series A round at \u20ac83.5 million. The round is led by Xgen Venture, Sofinnova Partners and CDP Venture Capital, with the participation of Panak\u00e8s Partners.  <\/strong>and another investor who prefers to remain anonymous.<\/p>\n\n<p>The funding will enable NanoPhoria to advance the development of its lead candidate, NP-MP1, through preclinical studies enabling IND (investigational new drug) application and early clinical development. NP-MP1 is a first-class peptide that acts on L-type cardiac calcium channels to improve ejection fraction, representing a new therapeutic strategy for the treatment of heart failure with reduced ejection fraction (HFrEF). <\/p>\n\n<p>Administered via NanoPhoria&#8217;s proprietary nano-in-micro lung-to-heart technology, NP-MP1 has demonstrated excellent efficacy in preclinical models of heart failure and aims to address one of the underlying causes of HFrEF by improving cardiac contractility. HFrEF is a condition that affects millions of people worldwide, with a five-year mortality rate of approximately 40%. <\/p>\n\n<p><strong>&#8220;This funding represents a transformative milestone for NanoPhoria,&#8221; said Claudio De Luca, CEO and co-founder, in a statement. &#8220;It allows us to accelerate the clinical development of NP-MP1 and expand our pipeline.<\/strong> Our innovative delivery platform enables us to reach previously inaccessible cellular targets in cardiomyocytes, bringing us closer to our goal of offering life-changing therapies to patients with serious and chronic heart conditions that are often inadequately treated by existing therapies. We are deeply grateful to our scientific founders, our investors, our Board of Directors and our Chair, Suman Shirodkar, whose vision and dedication have shaped NanoPhoria&#8217;s progress and ambitions. <\/p>\n\n<p>&#8220;This investment is perfectly in line with Xgen Venture&#8217;s strategy, which aims to lead the initial financing rounds of the most innovative Italian start-ups that respond to real medical needs,&#8221; says Paolo Fundar\u00f2, managing partner of Xgen Venture. &#8220;NanoPhoria&#8217;s science offers a new and concrete approach to delivering highly potent therapies directly to the heart, and we are excited to be working with a consortium of top-tier investors.&#8221;<\/p>\n\n<p>\u201cNanoPhoria\u2019s platform has the potential to redefine therapeutic paradigms in cardiovascular disease and other chronic conditions, which is why we are excited to invest in this company,\u201d adds Henrijette Richter, managing partner at Sofinnova Partners. . &#8220;This funding builds on the initial support provided by my colleague Lucia Faccio, partner in the Sofinnova Telethon strategy, whose role was instrumental in supporting the company in its early stages. The investment reflects Sofinnova&#8217;s broader commitment to supporting scientific excellence in Europe, from the creation of new companies to their advanced growth.&#8221; <\/p>\n\n<p>Founded in 2022 by Daniele Catalucci, Michele Iafisco, Alessio Alogna and Claudio De Luca, NanoPhoria is a spin-off of the National Research Council (CNR). The company is developing a versatile nano-in-micro and lung-to-heart delivery platform based on inorganic calcium phosphate nanoparticles. The company&#8217;s first product is a preclinical treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome that affects millions of people worldwide. (photo by <a href=\"https:\/\/unsplash.com\/it\/@joshua_chehov?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash\">Joshua Chehov<\/a> on <a href=\"https:\/\/unsplash.com\/it\/foto\/un-primo-piano-di-un-orologio-con-un-battito-cardiaco-su-di-esso-ANgv6jN1OUs?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash\">Unsplash<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The start-up is working on a treatment for heart failure and receives funding from Xgen Venture, Sofinnova, CDP VC, and Panak\u00e8s Partners<\/p>\n","protected":false},"author":125,"featured_media":147754,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1317],"tags":[1350,1143,1137,1136,1145],"companies":[2957],"journalist":[1518],"class_list":["post-147764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-funding-news","tag-biotech-en","tag-investments","tag-italy-en","tag-startup-en-2","tag-venture-capital-en-2","companies-nanophoria-en","journalist-editorial-staff-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","width":150,"height":100,"crop":false,"srcset":false,"alt":"malattia cardiaca"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","width":1024,"height":683,"crop":false,"srcset":false,"alt":"malattia cardiaca"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","width":2048,"height":1365,"crop":false,"srcset":false,"alt":"malattia cardiaca"}},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u20ac83.5 million Series A round for biotech company NanoPhoria<\/title>\n<meta name=\"description\" content=\"The start-up is working on a treatment for heart failure and receives funding from Xgen Venture, Sofinnova, CDP VC, and Panak\u00e8s Partners\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u20ac83.5 million Series A round for biotech company NanoPhoria\" \/>\n<meta property=\"og:description\" content=\"The start-up is working on a treatment for heart failure and receives funding from Xgen Venture, Sofinnova, CDP VC, and Panak\u00e8s Partners\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T07:57:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-06T10:45:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"3872\" \/>\n\t<meta property=\"og:image:height\" content=\"2581\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"\u20ac83.5 million Series A round for biotech company NanoPhoria\",\"datePublished\":\"2025-10-06T07:57:14+00:00\",\"dateModified\":\"2025-10-06T10:45:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/\"},\"wordCount\":500,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/joshua-chehov-ANgv6jN1OUs-unsplash.webp\",\"keywords\":[\"biotech\",\"investments\",\"italy\",\"startup\",\"venture capital\"],\"articleSection\":[\"Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/\",\"name\":\"\u20ac83.5 million Series A round for biotech company NanoPhoria\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/joshua-chehov-ANgv6jN1OUs-unsplash.webp\",\"datePublished\":\"2025-10-06T07:57:14+00:00\",\"dateModified\":\"2025-10-06T10:45:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"The start-up is working on a treatment for heart failure and receives funding from Xgen Venture, Sofinnova, CDP VC, and Panak\u00e8s Partners\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/e83-5-million-series-a-round-for-biotech-company-nanophoria\\\/147764\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/joshua-chehov-ANgv6jN1OUs-unsplash.webp\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/joshua-chehov-ANgv6jN1OUs-unsplash.webp\",\"width\":3872,\"height\":2581,\"caption\":\"malattia cardiaca\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u20ac83.5 million Series A round for biotech company NanoPhoria","description":"The start-up is working on a treatment for heart failure and receives funding from Xgen Venture, Sofinnova, CDP VC, and Panak\u00e8s Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/","og_locale":"en_US","og_type":"article","og_title":"\u20ac83.5 million Series A round for biotech company NanoPhoria","og_description":"The start-up is working on a treatment for heart failure and receives funding from Xgen Venture, Sofinnova, CDP VC, and Panak\u00e8s Partners","og_url":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/","og_site_name":"Startupbusiness.it","article_published_time":"2025-10-06T07:57:14+00:00","article_modified_time":"2025-10-06T10:45:25+00:00","og_image":[{"width":3872,"height":2581,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","type":"image\/webp"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"\u20ac83.5 million Series A round for biotech company NanoPhoria","datePublished":"2025-10-06T07:57:14+00:00","dateModified":"2025-10-06T10:45:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/"},"wordCount":500,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","keywords":["biotech","investments","italy","startup","venture capital"],"articleSection":["Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/","url":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/","name":"\u20ac83.5 million Series A round for biotech company NanoPhoria","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","datePublished":"2025-10-06T07:57:14+00:00","dateModified":"2025-10-06T10:45:25+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"The start-up is working on a treatment for heart failure and receives funding from Xgen Venture, Sofinnova, CDP VC, and Panak\u00e8s Partners","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/e83-5-million-series-a-round-for-biotech-company-nanophoria\/147764\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/10\/joshua-chehov-ANgv6jN1OUs-unsplash.webp","width":3872,"height":2581,"caption":"malattia cardiaca"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Funding News"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/147764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=147764"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/147764\/revisions"}],"predecessor-version":[{"id":147765,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/147764\/revisions\/147765"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/147754"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=147764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=147764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=147764"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=147764"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=147764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}